Business
AMBU_B: Strong Q1 growth in endoscopy and urology, with EBIT margin on track despite tariff and FX headwinds
AMBU_B: Strong Q1 growth in endoscopy and urology, with EBIT margin on track despite tariff and FX headwinds
About this update from Ambu A/s Class B
Q1 delivered 8.6% organic revenue growth, led by endoscopy (14.4%) and strong urology/respiratory momentum. EBIT margin was 10.5% (adjusted >15% excluding tariffs/FX), with full-year guidance maintained and tariff/FX headwinds expected to ease in H2.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.